Reviewing SOPHiA GENETICS (SOPH) and Its Peers

SOPHiA GENETICS (NASDAQ:SOPHGet Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare SOPHiA GENETICS to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.


This table compares SOPHiA GENETICS and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SOPHiA GENETICS -204.31% -37.98% -31.92%
SOPHiA GENETICS Competitors -4,589.88% -66.41% -30.18%

Valuation & Earnings

This table compares SOPHiA GENETICS and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SOPHiA GENETICS $40.45 million -$73.68 million -3.05
SOPHiA GENETICS Competitors $773.46 million $147.16 million -0.08

SOPHiA GENETICS’s peers have higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for SOPHiA GENETICS and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS 0 0 4 0 3.00
SOPHiA GENETICS Competitors 1649 5719 11364 210 2.54

SOPHiA GENETICS currently has a consensus price target of $20.67, suggesting a potential upside of 364.42%. As a group, “Biological products, except diagnostic” companies have a potential upside of 122.76%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, equities analysts plainly believe SOPHiA GENETICS is more favorable than its peers.

Institutional & Insider Ownership

27.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.5% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


SOPHiA GENETICS peers beat SOPHiA GENETICS on 7 of the 12 factors compared.

SOPHiA GENETICS Company Profile (Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with's FREE daily email newsletter.